Today: December 12, 2018, 4:07 am
  
Business

CrownBio Enters Strategic Partnership with Phanes Therapeutics to Accelerate Discovery and Development of Phanes' Novel Oncology Agents

PR-Inside.com: 2018-03-13 13:03:03

SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Phanes Therapeutics as a strategic partner to advance their oncology drug discovery pipeline.

CrownBio provides the world's largest collection of Patient-Derived Xenograft (PDX) models and is a leading provider of integrated oncology solutions that enable development of cutting-edge cancer treatments. Phanes will gain access to CrownBio's clinically relevant CDX models, exclusive PDX models and robust in vitro assays to propel their innovative drug discovery pipeline.

Dr. Ming Wang, President and CEO of Phanes Therapeutics, expressed enthusiasm about this partnership, "We are an innovative drug discovery company with a robust pipeline and need access to top notch in vivo pharmacology efficacy models to quickly evaluate and advance our lead molecules. We are very glad to partner with CrownBio.  They have very unique MuPrime(TM) models, as well as Humanized GEMMs (HuGEMM(TM)) and Patient-Derived Xenograft (PDX) models for our oncology programs. We look forward to a productive partnership."

"We are very pleased that Phanes Therapeutics has selected us as a trusted partner to advance their leading-edge oncology compounds," said Laurie Heilmann, CrownBio's Chief Business Officer. "Our unique capabilities will help Phanes efficiently and thoroughly assess drugs in their pipeline to identify and advance candidates showing the most promise for improved treatment of cancer."

About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.

About Phanes Therapeutics
Phanes Therapeutics is a biotech company with strong innovative drug discovery and development programs in metabolic complications and oncology areas. It was founded by former Janssen/J&J Vice President Ming Wang, PhD, MBA. The company focuses exclusively on biologics drug discovery with multiple first-in-class and best-in-class molecules in its pipeline. For more information on Phanes, please visit www.phanesthera.com.

Media Enquiries:

Jody Barbeau
Crown Bioscience Inc. 
marketing@crownbio.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire




# 562 Words
Related Articles
More From The Author
Telenor Group and Ant Financial in strategic [..]
(Fornebu, Norway and Hangzhou, China, March 13, 2018) Telenor Group has reached a strategic partnership agreement with Ant [..]
coMakeIT Appoints a New CTO and Launches [..]
Announcing this new initiative, Steven ten Napel : “The charter of our TIC is to help drive innovation for Independent [..]
Cypress Drills 121 meters of 1146 ppm [..]
VANCOUVER, British Columbia, March 13, 2018 (GLOBE NEWSWIRE) -- Cypress Development Corp. (TSX-V:CYP) (OTCBB:CYDVF) (Frankfurt:C1Z1) ("Cypress" [..]
Willis Lease Finance Corporation Reports 50% Growth [..]
NOVATO, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ:WLFC) today reported 50.4% growth in [..]
LexinFintech Holdings Ltd. to Report Fourth Quarter [..]
SHENZHEN, China, March 13, 2018 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. ("Lexin" or the "Company") (NASDAQ:LX), [..]
 
More From Business
Cross Talks Awarded $5K Grant from the [..]
The Penn State Brandywine Boost, a program of the Invent Penn State initiative, has selected Delaware State Chamber Member, Soraya [..]
Huber Needles: Market is likely to register [..]
This Market Study provides key insights and forecast on the global Huber needles market for the forecast period 2017-2024. The [..]
GTA Boosting Offers the Best Way to [..]
10 December 2018 – GTA Boosting is offering the most effective and straightforward way to buy gta online money in [..]
Purtier Sales Is The Amazing New Solution [..]
Los Angeles, USA — 6 December 2018 — Purtier Sales is the web site that encourages people to buy the [..]
GPU Servers Offers the Best Quality Service
6 December 2018 – GPU Servers is offering the very best way to make the most from the gpu dedicated [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.